目的 探讨清热化痰宣肺汤治疗痰热壅肺型重症肺炎的临床效果。方法 选择2022年3月—2023年6月天津市中西医结合医院收治的158例痰热壅肺型重症肺炎患者进行探讨,采用随机分组法分为研究组和对照组,每组各79例,对照组接受常规对症处理联合抗生素治疗,研究组在对照组基础上给予清热化痰宣肺汤,两组均治疗2周,比较疗效、中医证候积分、肺功能、血气分析结果以及不良反应发生情况。结果 研究组总有效率为94.94%,高于对照组的84.81（P=0.035）;研究组治疗后发热、痰壅以及气促评分分别为（1.12±0.33）分、（1.02±0.28）分及（1.16±0.30）分;对照组治疗后发热、痰壅以及气促评分分别为（1.45±0.36）分、（2.11±0.42）分及（2.06±0.39）分,研究组和对照组各项评分均较治疗前降低（均P<0.05）,研究组低于对照组（P均<0.05）;治疗后研究组PEF、FEV₁、FVC以及MVV分别为（3.48±0.53）L/s、（2.95±0.52）L、（2.98±0.58）L、（88.15±5.25）L/min,治疗后对照组的PEF、FEV₁、FVC以及MVV分别为（4.22±0.53）L/s、（2.41±0.47）L、（2.98±0.58）L、（88.15±5.25）L/min,两组均较治疗前升高（均P<0.05）,且研究组高于对照组（均P<0.05）; 治疗后研究组和对照组PaO₂分别为（9.77±1.12）kPa、（9.33±1.09）kPa,均较治疗前升高（均P<0.05）,研究组高于对照组（P=0.013）,治疗后研究组和对照组的PaCO₂分别为（4.22±0.14）kPa、（5.11±0.16）kPa,均较治疗前下降（均P<0.05）,研究组低于对照组（P<0.001）;研究组出现3例恶心不良反应,对照组未见不良反应发生,组间无显著差异（P>0.05）。结论 清热化痰宣肺汤治疗痰热壅肺型重症肺炎效果理想,可明显改善肺功能及血气指标,且具有较高安全性。

目的 评价SAMe-TT₂R₂评分对非瓣膜性房颤使用华法林的患者中的抗凝疗效的评估作用,探讨SAMe-TT₂R₂评分与缺血性卒中事件、出血事件的相关性。方法 以石河子大学医学院第一附属医院2018年1月—2019年1月住院治疗,确诊为非瓣膜性房颤并口服华法林抗凝的患者作为观察对象,进行为期10月的随访。通过患者的国际标准化比值(INR),计算患者的抗凝治疗范围内时间百分比(Time in Therapeutic Range, TTR),并对所有患者进行SAMe-TT₂R₂评分。运用χ²检验、Spearman秩相关、ROC曲线分析评估SAMe-TT₂R₂评分对患者抗凝疗效的预测能力。随访期内收集缺血性卒中和出血事件的发生情况,分析上述事件与SAMe-TT₂R₂评分的相关性。结果 190例患者平均TTR为(46.76±21.99)％,SAMe-TT₂R₂分数与患者的TTR呈负相关(P=0.001),ROC曲线下面积为0.661,P=0.001,约登指数0.203对应的临界值取整数为4分,敏感度和特异度分别为72.6％和47.7％,提示SAMe-TT₂R₂对预测TTR<65％有一定的价值。随访期间共有5例患者发生缺血性卒中事件,25例患者发生不同程度出血事件,11例患者发生全因死亡事件,上述事件在各个SAMe-TT₂R₂分值的发生分布差异无统计学意义(P＞0.05)。结论 在非瓣膜性房颤并使用华法林抗凝治疗的患者中,SAMe-TT₂R₂评分对使用华法林抗凝治疗患者的抗凝有效性具有一定的预测能力,可将SAMe-TT₂R₂评分作为预测华法林抗凝疗效的预测的指标。

Objective To evaluate the anticoagulant effect of SAMe-TT₂R₂ in patients with non-valvular atrial fibrillation treated with warfarin, and to explore the correlation between SAMe-TT₂R₂ and ischemic stroke events and bleeding events. Methods Patients who were diagnosed as non-valvular atrial fibrillation and with oral warfarin were enrolled in the First Affiliated Hospital of Shihezi University School of Medical College in January 2018-January 2019, and for 10 months of follow-up. Collecting patients' International normalization ratio(INR), calculating the Time in therapeutic range(TTR), and the SAMe-TT2 R2 score. And χ² test, Spearman rank correlation and ROC curve analysis were used to evaluate the predictive ability of SAMe-TT2 R2 score on anticoagulant efficacy in patients. Follow-up was conducted to investigate the incidence of ischemic stroke or hemorrhagic events and explore the relationship with the SAMe-TT2 R2 score. Results The mean TTR of 190 patients was 46.76%±21.99%, and the score of SAMe-TT_{2 R2} was negatively correlated with the TTR of the patients(P=0.001), the area under the ROC curve was 0.661, P=0.001, The critical value corresponding was 4 points, and the sensitivity and specificity were 72.6% and 47.7%, respectively suggesting that SAMe-TT₂R₂ had certain value in predicting TTR< 65%. During follow-up, a total of 5 patients had ischemic stroke, 25 patients had different degrees of bleeding, and 11 patients had all-cause death, different SAMe-TT₂R₂ scores showed no statistical significance(P>0.05). Conclusion In patients with non-valvular atrial fibrillation treated with warfarin anticoagulant, the SAMe-TT₂R₂ score has a certain predictive ability for the anticoagulant efficacy of patients treated with warfarin anticoagulant, and the SAMe-TT₂R₂ score could be used as an indicator for predicting the anticoagulant efficacy of warfarin.